Boston Scientific Corporation (BSX) vs Regeneron Pharmaceuticals, Inc. (REGN)
REGN leads on 11 of 16 compared metrics.
A side-by-side comparison of Boston Scientific Corporation and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 17, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
BSX
Boston Scientific Corporation
$46.92Healthcare
REGN
Regeneron Pharmaceuticals, Inc.
$614.98Healthcare
Total return — BSX vs REGN
growth of $100 · last 30yBSX +372.2%REGN +3533.9%REGN compounded faster
Log scale — wide-divergence pair
BSX REGN
BSX vs REGN: by the numbers
- •BSX is the larger company ($69.74B vs $62.78B market cap).
- •REGN trades at the lower earnings multiple (14.98 vs 19.71 P/E).
- •REGN converts more revenue to profit (29.65% vs 17.24% net margin).
- •BSX grew revenue faster over the past five years (15.29% vs 10.16% CAGR).
- •REGN pays a dividend (0.59% yield) while BSX does not currently pay one.
Which is better, BSX or REGN?
Metric tally: BSX 5 · REGN 11It depends on what you're optimizing for:
ValueREGN(lower P/E)
GrowthBSX(faster 5Y revenue CAGR)
QualityBSX(higher ROIC)
Metrics side by side
Valuation
| Metric | BSX | REGN |
|---|---|---|
| P/E ratio | 19.71 | 14.98● |
| Forward P/E | 12.60 | 11.36● |
| P/S ratio | 3.40● | 4.44 |
| P/B ratio | 2.71 | 2.11● |
| PEG ratio | 0.88● | 3.38 |
| EV / EBITDA | 14.07 | 11.48● |
| FCF yield | 4.91% | 6.27%● |
Profitability
| Metric | BSX | REGN |
|---|---|---|
| Gross margin | 70.41% | 84.55%● |
| Operating margin | 20.12% | 24.32%● |
| Net margin | 17.24% | 29.65%● |
| ROE | 13.74% | 14.08%● |
| ROIC | 8.78%● | 8.51% |
Dividends
| Metric | BSX | REGN |
|---|---|---|
| Dividend yield | — | 0.59% |
| Payout ratio | — | 8.45% |
Growth (annualized)
| Metric | BSX | REGN |
|---|---|---|
| Revenue CAGR (5Y) | 15.29%● | 10.16% |
| EPS CAGR (5Y) | -8.67% | 5.70%● |
| FCF CAGR (5Y) | 19.89%● | 15.42% |
| Total return CAGR (5Y) | 1.86% | 3.22%● |
Frequently asked
- Which is better, BSX or REGN?
- It depends on your goal. value: REGN (lower P/E); growth: BSX (faster 5Y revenue CAGR); quality: BSX (higher ROIC). Across all compared metrics, REGN leads 11 to 5.
- Is BSX or REGN cheaper?
- On trailing earnings, REGN is cheaper: BSX trades at a 19.71 P/E and REGN at 14.98.
- Which has grown faster, BSX or REGN?
- Over the past five years, BSX grew revenue faster — BSX at a 15.29% CAGR versus REGN at 10.16%.
- Does BSX or REGN pay a bigger dividend?
- REGN pays a dividend (0.59% yield) while BSX does not currently pay one.
- Is BSX or REGN more profitable?
- REGN runs the higher net margin — BSX at 17.24% versus REGN at 29.65%.
- Which has been the better investment, BSX or REGN?
- Over the past 10-year, BSX delivered the higher annualized total return — BSX at 7.47% versus REGN at 5.29%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Boston Scientific P/E ratioRegeneron Pharmaceuticals P/E ratioBoston Scientific dividend yieldRegeneron Pharmaceuticals dividend yieldBoston Scientific ROERegeneron Pharmaceuticals ROEBoston Scientific operating marginRegeneron Pharmaceuticals operating marginBoston Scientific revenue growthRegeneron Pharmaceuticals revenue growthBoston Scientific free cash flowRegeneron Pharmaceuticals free cash flow
Boston Scientific & Regeneron Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 17, 2026.